Overview / Abstract: |
In 2017, 46 new medicines were approved by the FDA – the highest number of approvals in 21 years. Scott Gottlieb, who was sworn in as FDA Commissioner in May 2017, has made use of policy changes put into effect during recent years to accelerate the approval process. This issue of The Rx Consultant focuses on new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: venous thromboembolism prophylaxis, atopic dermatitis, hepatitis C infection, psoriasis, HER2-positive breast cancer, Parkinson disease, Huntington disease, tardive dyskinesia, and bacterial vaginosis. |
Expiration |
Mar 22, 2021 |
Discipline(s) |
Nurse Practitioner , Pharmacy CPE |
Format |
Monograph, Online |
Cost |
10.00 |
Credits / Hours |
2.0 |
Accreditation |
ACPE |
Presenters / Authors / Faculty |
James Chan, PharmD, PhD |
Keywords / Search Terms |
Continuing Education Network Inc. venous thromboembolism prophylaxis, atopic dermatitis, hepatitis C infection, psoriasis, HER2-positive breast cancer, Parkinson disease, Huntington disease, tardive dyskinesia, bacterial vaginosis, The Rx Consultant |